Clinical Trials Browser

Phase 1/2 × Nasopharyngeal Neoplasms × Bevacizumab × Clear all

NCT03813394 2024-11-22

2018/00947

Phase 1/2 Active not recruiting

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections